First-in-Human trial tests engineered immune cells against Tough-to-Treat colon cancer
NCT ID NCT05319314
Summary
This is an early-stage safety study testing a new type of personalized cell therapy called GCC19CART for adults with metastatic colorectal cancer that has come back or stopped responding to standard treatments. The study aims to find a safe dose and see how well the body tolerates the treatment. Researchers will also gather initial information on whether the therapy helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215-5418, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California San Francisco Medical Center
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Hospital - Anschutz Cancer Pavilion
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.